Seres Therapeutics
Presence
Seres Therapeutics is one of the...
Seres Therapeutics is a company listed under the stock ticker MCRB (US).
Executives
View the org chart displaying its 16 main executives
Most searched biographies at Seres Therapeutics
- Eric Shaff, Director, President and Chief Executive Officer
- Stephen Berenson, Chairman of the Board
- Paul Biondi, Director
Popular executive movements at Seres Therapeutics
- Marella Thorell has joined the company as Chief Financial Officer (posted on February 26 2024).
- David Arkowitz, Executive Vice President, Chief Financial Officer and Head of Business Development, is retiring (posted on February 26 2024).
Create your alert
to follow the executive moves at Seres Therapeutics.
Biotechnology
Seres Therapeutics has 2,280 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Seres Therapeutics
- Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference | Seres Therapeutics
- Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates | Seres Therapeutics
- Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022 | Seres Therapeutics
- Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock | Seres Therapeutics
- Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection | Seres Therapeutics
- Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | Seres Therapeutics
- Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
- Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
- Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates | Seres Therapeutics
- Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022 | Seres Therapeutics
- View more press releases Close
Social media about Seres Therapeutics
- Seres Therapeutics on Wikipedia, Google News & Yahoo Finance
- Seres Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Eric Shaff 
Call Seres Therapeutics at +1 617...
